- Report
- January 2024
- 200 Pages
Global
From €3996EUR$4,150USD£3,437GBP
- Report
- April 2023
- 112 Pages
Global
From €4574EUR$4,750USD£3,934GBP
- Report
- May 2022
- 47 Pages
Global
From €1926EUR$2,000USD£1,656GBP
- Report
- December 2022
- 220 Pages
Global
From €5518EUR$5,730USD£4,746GBP
Ethinylestradiol is a synthetic form of the female sex hormone oestrogen, used in combination with other hormones to treat a range of sexual and reproductive health conditions. It is used in combination with progestogens in hormonal contraceptives, such as the combined oral contraceptive pill, to prevent pregnancy. It is also used to treat menopausal symptoms, such as hot flashes, and to treat endometriosis and polycystic ovary syndrome.
Ethinylestradiol is available in a range of formulations, including tablets, patches, and implants. It is also used in combination with other hormones in hormone replacement therapy for postmenopausal women.
The market for ethinylestradiol is driven by the increasing prevalence of sexual and reproductive health conditions, as well as the growing demand for contraception. The availability of generic versions of ethinylestradiol has also contributed to the growth of the market.
Some of the major companies in the ethinylestradiol market include Pfizer, Merck, Bayer, Teva Pharmaceuticals, and Mylan. Show Less Read more